IDEXX Laboratories, Inc.

Equities

IDXX

US45168D1046

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 10:10:14 2024-04-18 am EDT			5-day change	1st Jan Change
477.9 ^USD	-0.07%		-5.41%	-14.27%

Apr. 01	Elanco Animal Health Appoints Two Ancora Holdings' Nominees to Board	MT
Apr. 01	Elanco appoints two directors after settling with activist Ancora	RE

IDEXX Laboratories : to Present at Raymond James Institutional Investors Conference

February 29, 2016 at 04:23 pm EST

WESTBROOK, Maine, Feb. 29, 2016 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX) announced today that it will participate in the Raymond James 37(th) Annual Institutional Investors Conference. Brian McKeon, Executive Vice President and Chief Financial Officer, is scheduled to make a presentation on the Company on Tuesday, March 8, 2016 at 2:15 p.m. (EST), at the JW Marriott Grande Lakes, Orlando, Florida. Individuals can access the live audio webcast of the presentation through a link on the home page of the IDEXX Laboratories website, www.idexx.com. An archived edition of the presentation will be available for 14 days via the same link.

https://photos.prnewswire.com/prnvar/20110602/NE13041LOGO

About IDEXX Laboratories
IDEXX Laboratories, Inc. is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for livestock and poultry and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX Laboratories employs more than 6,000 people and offers products to customers in over 175 countries.

Contact: Bonnie Reid, Investor Relations, (207) 556-8155

Logo - http://photos.prnewswire.com/prnh/20110602/NE13041LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/idexx-laboratories-to-present-at-raymond-james-institutional-investors-conference-300227967.html

SOURCE IDEXX Laboratories, Inc.

Latest news about IDEXX Laboratories, Inc.

Elanco Animal Health Appoints Two Ancora Holdings' Nominees to Board	Apr. 01	MT
Elanco appoints two directors after settling with activist Ancora	Apr. 01	RE
Elanco appoints two directors to its board after agreement with Ancora	Apr. 01	RE
Idexx Laboratories: Superior growth prospects	Mar. 11
Idexx Laboratories Insider Sold Shares Worth $790,427, According to a Recent SEC Filing	Mar. 07	MT
Idexx Laboratories Insider Sold Shares Worth $4,525,596, According to a Recent SEC Filing	Mar. 07	MT
Transcript : IDEXX Laboratories, Inc. Presents at 45th Annual Raymond James Institutional Investors Conference 2024, Mar-04-2024 11:00 AM	Mar. 04
Ancora seeks four board seats at Elanco amid push for changes	Feb. 29	RE
Transcript : IDEXX Laboratories, Inc. Presents at Bank of America 2024 Animal Health Virtual Summit, Feb-29-2024 10:50 AM	Feb. 29
Ancora seeks four board seats at Elanco amid push for changes, sources say	Feb. 29	RE
ANALYST RECOMMENDATIONS : Coinbase, Fortinet, Nike, Chipotle, Nvidia...	Feb. 16
Idexx Launches Vellotm, an Innovative Pet Owner Engagement Software Solution, Streamlining How Practices and Clients Connect	Feb. 15	CI
Pet products maker Zoetis sees annual profit below estimates on weak demand	Feb. 13	RE
Idexx Laboratories Insider Sold Shares Worth $6,871,319, According to a Recent SEC Filing	Feb. 09	MT
Idexx Laboratories Insider Sold Shares Worth $13,295,975, According to a Recent SEC Filing	Feb. 09	MT
Idexx Laboratories Insider Sold Shares Worth $4,704,559, According to a Recent SEC Filing	Feb. 09	MT
JPMorgan Adjusts Price Target on IDEXX Laboratories to $630 From $600, Maintains Overweight Rating	Feb. 06	MT
Morgan Stanley Lifts PT on IDEXX Laboratories to $620 From $600 After 'Impressive' Q4 2023 Upside, 'Solid' 2024 Guide; Overweight Kept	Feb. 06	MT
Barclays Adjusts Price Target on IDEXX Laboratories to $655 From $605, Keeps Overweight Rating	Feb. 06	MT
Stifel Adjusts Price Target on IDEXX Laboratories to $570 From $525, Keeps Hold Rating	Feb. 06	MT
IDEXX Laboratories Shares Rise After Q4 Beat	Feb. 05	MT
IDEXX Laboratories Seeks Acquisitions	Feb. 05	CI
Transcript : IDEXX Laboratories, Inc., Q4 2023 Earnings Call, Feb 05, 2024	Feb. 05
IDEXX Laboratories sees 2024 revenue above estimates	Feb. 05	RE
IDEXX Laboratories' Q4 Earnings, Revenue Increase	Feb. 05	MT

Chart IDEXX Laboratories, Inc.

Duration

Period

More charts

Company Profile

IDEXX Laboratories, Inc. is a world leader in the design, development and marketing of diagnostic test instruments for animal health monitoring and analysis of dairy products and water. Net sales break down by area of application as follows: - veterinary diagnoses for pets (91.6%); - water quality analysis (4.6%); - veterinary diagnoses for livestock and poultry (3.3%): solutions that help detect infectious diseases in ruminants, pigs, poultry and horses. The group also offers test solutions for dairy products; - other (0.5%). Net sales by source of income break down between product sales (57.1%) and services (42.9%). Net sales are distributed geographically as follows: the United States (65.3%), Canada (4.1%), Americas (2.3%), Germany (4.1%), the United Kingdom (3.3%), France (2.7%), Italy (1.5%), Spain (1.4%), Switzerland (0.9%), the Netherlands (0.8%), Europe/Middle East/Africa (4.8%), Australia (2.6%), Japan (2.1%), China (1.2%) and Asia/Pacific (2.9%).

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-01 - Q1 2024 Earnings Release

Related indices

S&P 500

More about the company